Drug Approval | May 03, 2025
Neuland Laboratories completes USFDA inspection at Unit 2
The FDA issued Form 483 with one observation related to building and facility management
The FDA issued Form 483 with one observation related to building and facility management
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
The Subsidiary has received one inspectional observation in Form 483
Alembic Pharmaceuticals commissions new facility at Pithampur
The inspection concluded with 6 observations and none of them were related to Data Integrity
Delivers robust earnings performance, successfully navigating a dynamic environment
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Distribution agreement enables FUJIFILM India to offer Spectra Logic advanced tape libraries and software solutions to enterprise customers and channel partners
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Subscribe To Our Newsletter & Stay Updated
